August 2015 | DelveInsight Business Research

Month: August 2015

LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists – Pipeline Insights, 2015-A DelveInsight Report

Aug 25, 2015• Uncategorized

New Approach Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

Aug 10, 2015• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

Introduction: Cardiovascular disease is the leading cause of mortality worldwide due to increased level of Low Density Lipoprotein,...

Warm Autoimmune Ahemolytic anemia Epidemiology forecast Segmentation, Treatment approaches, and WAIHA market forecast
Articles, Business Consultant, Pharma Consultant
Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies.
Business Consultant, News, Pharma Consultant
Telemedicine: Can it be the future of healthcare?
Articles, Business Consultant, Pharma Consultant
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M;
Business Consultant, News, Pharma Consultant
Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared?
Articles, Business Consultant, Pharma Consultant
What is driving Retinitis pigmentosa market forward?
Articles, Business Consultant, Pharma Consultant
FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million
Business Consultant, News, Pharma Consultant
Bioelectronic Medicine: Applications and Future Prospects
Articles, Business Consultant, Pharma Consultant
Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid
Business Consultant, News, Pharma Consultant
Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence
Articles, Business Consultant, Pharma Consultant